Status:
SUSPENDED
Virtual Reality to Reduce Delirium
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Collaborating Sponsors:
University of Bern
Conditions:
Delirium
Cognitive Impairment
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Delirium has been long considered as a major contributor to cognitive impairments following a critical illness. Currently, both pharmacologic and non-pharmacologic prevention and treatment strategies ...
Eligibility Criteria
Inclusion
- Written Informed Consent (by the patient, relatives, or authorized representative)
- No severe visual or auditory impairments (strabismus, macular degeneration, retinopathy)
- Estimated length of stay \>24 hours
- Can keep eyes open for at least 30 seconds
- German or French speaking
Exclusion
- Known psychotic disorders associated with delusions (e.g. schizophrenia)
- Recent history of major depression
- Admission for drug overdose
Key Trial Info
Start Date :
April 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
920 Patients enrolled
Trial Details
Trial ID
NCT04498585
Start Date
April 14 2021
End Date
June 1 2023
Last Update
February 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Inselspital
Bern, Switzerland, 3010